The overall goal of this program is to develop strategies for treating patients with hematologic malignancies by using radiolabeled monoclonal antibodies. Our studies to date have demonstrated the feasibility of treating patients with antibody labeled with relatively high amounts of I- 131 and of overcoming the resulting myelosuppression by marrow transplantation. In a Phase I study of lymphoma, nearly all treated patients achieved a complete response, some of which are enduring now for more than three years in the absence of significant non-hematopoietic toxicity. Consequently, we are proposing to continue to study patients with hematologic malignancies including B-cell lymphomas and acute leukemia. In these projects we will continue to assess the biodistribution and radiation dosimetry of radiolabeled antibodies and treat patients in whom favorable dosimetry is achieved. Specifically, in Project I, we will continue to evaluate radiolabeled antibodies that react with both normal and malignant B-cells for treating patients with lymphoma. These studies will combine targeted radiation with high dose therapy regimens prior to autologous marrow transplantation. In Project II, we will evaluate the use of anti-myeloid monoclonal antibodies in patients with acute leukemia for delivering radiation to tumor and to the bone marrow where this tumor resides. In these studies, radiation delivered by antibody will be in addition to total body irradiation and/or chemotherapy, as part of a preparative regimen prior to marrow transplantation. In Project III we will evaluate if improved delivery of radiation to tumor can be achieved using different antibodies and/or radionuclides. Radioimmunoconjugates selected in preclinical studies will be evaluated in patients using quantitative imaging methods developed in this project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA044991-11
Application #
2700407
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Reynolds, Craig W
Project Start
1988-06-01
Project End
2000-04-30
Budget Start
1998-05-01
Budget End
1999-04-30
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Green, Damian J; O'Steen, Shyril; Lin, Yukang et al. (2018) CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood 131:611-620
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Greenbaum, Adam M; Green, Damian J; Holmberg, Leona A et al. (2018) Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Res 53:223-226
Green, Damian J; Press, Oliver W (2017) Whither Radioimmunotherapy: To Be or Not To Be? Cancer Res 77:2191-2196
O'Steen, Shyril; Green, Damian J; Gopal, Ajay K et al. (2017) Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res 77:3885-3893
Cowan, Andrew J; Stevenson, Phillip A; Gooley, Ted A et al. (2017) Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. Br J Haematol 176:583-590
Shadman, Mazyar; Gopal, Ajay K; Kammerer, Britt et al. (2016) Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leuk Lymphoma 57:572-6
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Graf, Solomon A; Gopal, Ajay K (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17:265-74
Chen, Robert; Gopal, Ajay K; Smith, Scott E et al. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-6

Showing the most recent 10 out of 133 publications